June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Spectroscopic characterization of perfluorohexyloctane, an eye drop for dry eye disease
Author Affiliations & Notes
  • Douglas Borchman
    Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Louisville, Kentucky, United States
  • Jason Vittitow
    Bausch and Lomb, Bridgewater, New Jersey, United States
  • Robert Kissling
    Bausch and Lomb, Bridgewater, New Jersey, United States
  • Thomas James Millar
    Beyond700, New South Wales, Australia
  • Neal Stolowich
    Chemistry, University of Louisville College of Arts and Sciences, Louisville, Kentucky, United States
  • Footnotes
    Commercial Relationships   Douglas Borchman Bausch and Lomb, Code C (Consultant/Contractor); Jason Vittitow Bausch and Lomb, Code E (Employment); Robert Kissling Bausch and Lomb, Code E (Employment); Thomas Millar Beyond700, Code E (Employment); Neal Stolowich None
  • Footnotes
    Support   Bausch + Lomb, a division of Bausch Health US, LLC
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3975. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Douglas Borchman, Jason Vittitow, Robert Kissling, Thomas James Millar, Neal Stolowich; Spectroscopic characterization of perfluorohexyloctane, an eye drop for dry eye disease. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3975.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Perfluorohexyloctane (PFHO, NOVO3) is under review at the Food and Drug Administration in the United States for the treatment of dry eye disease associated with Meibomian gland dysfunction. PFHO provides relief of dry eye signs and symptoms and has been shown to have potent anti-evaporative action. In addition, PFHO has been shown to solubilize certain Meibum lipids. However, its precise mode(s) of action is still being elucidated.

Methods : Infrared emissivity (Tearview™) was used to investigate the interaction of PFHO on a buffered salt solution and with human Meibum in vitro and to visualize PFHO on the surface of the eye of a 69 year-old Caucasian volunteer following instillation of 30 µl PFHO. Emissivity images were converted to tif formats, exported to PHOTO-PAINT 12 (Corel) for quantitative analysis of grey-scale pixels over time. Because of its high emissivity, PFHO appears white in images. 1H- and 19F-nuclear magnetic resonance was used to measure O2 in PFHO.

Results : In vitro emissivity images showed that PFHO layers on the surface of buffer, expanding at a mean (SD) rate of 0.98 (14) cm2/sec at 35oC, and disappears at a rate of 0.050 (0.002) and 0.122 (0.005) µL/minute at 25 and 35oC, respectively, consistent with reported rates of evaporation for PFHO. PFHO’s expansion rate was not impacted by the addition of mucin (1-50 mg/mL) to buffer (P≥0.11). Addition of PFHO to a static 129-nm thick film of Meibum applied to the surface of buffer, without stirring, showed that PFHO spread over it. In vivo, PFHO emissivity was visible as white streaks on the ocular surface for the full 2-hour duration of emissivity testing following instillation PFHO. NMR analysis showed a mean (SD) partial pressure of O2 in PFHO of 257 (36) and 270 (38) mm Hg at 25 and 37oC, respectively, 62.5% higher than that of tears in equilibrium with air.

Conclusions : The current IR emissivity data add support to the benefits of PFHO as an eye drop therapy for dry eye disease. Taken with previous data, PFHO quickly spreads on the surface of the tear film lipid-layer, appears unaffected by the presence of mucin, and forms a long-lasting anti-evaporative barrier. Given its high oxygen-content, PFHO may deliver O2 to the cornea to facilitate surface healing.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×